CAC 40
8 219,14 +31,49 (+0,38 %) Euro Stoxx 50
5 085,08 +30,67 (+0,61 %) Dow Jones
39 512,84 +125,08 (+0,32 %) EUR/USD
1,0772 -0,0012 (-0,11 %) Gold future
2 366,90 +26,60 (+1,14 %) Bitcoin EUR
56 381,90 -2 067,68 (-3,54 %)
WuXi Biologics (Cayman) Inc. (2269.HK)
WuXi Biologics (Cayman) Inc.
No. 108, Meiliang Road
Mashan
Wuxi 214092
China
https://www.wuxibiologics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 12 740
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman | S.O. | S.O. | 1967 |
| Dr. Zhisheng Chen | CEO & Executive Director | 4,32M | S.O. | 1973 |
| Dr. Weichang Zhou Ph.D. | Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director | 4,3M | S.O. | 1964 |
| Mr. Ming Tu | CFO & Executive VP | S.O. | S.O. | 1968 |
| Lihua Yu M.B.A. | COO & Senior VP | S.O. | S.O. | S.O. |
| Dr. Sherry Gu Ph.D. | Chief Technology Officer and Executive VP of Global Biologics Development Department | S.O. | S.O. | 1971 |
| Dr. Jijie Gu Ph.D. | Chief Scientific Officer & President of Global Biologics Research | S.O. | S.O. | 1966 |
| Lina Fan Ph.D. | Senior VP & Head of Investor Relations | S.O. | S.O. | S.O. |
| Ms. Cong Ding J.D. | VP & Head of Legal Department | S.O. | S.O. | S.O. |
| He Wang | Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management | S.O. | S.O. | S.O. |
Description
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Gouvernance d’entreprise
L’ISS Governance QualityScore de WuXi Biologics (Cayman) Inc. en date du 1 mai 2024 est 10. Les scores principaux sont Audit : 2; Société : 10; Droits des actionnaires : 4; Compensation : 9.
